CX3CR1 and ovarian carcinoma: Furthermore, AZD8797 was described as an allosteric inhibitor of CX3CR1 [37]; however, it is not known whether it leads to the same changes in the receptor conformation and affects the downstream signaling cascades in all tested ovarian cancer cell lines similarly.